These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10878722)

  • 1. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    Lupus; 2000; 9(5):322-7. PubMed ID: 10878722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.
    Smolen JS; Strand V; Cardiel M; Edworthy S; Furst D; Gladman D; Gordon C; Isenberg DA; Klippel JH; Petri M; Simon L; Tugwell P; Wolfe F
    J Rheumatol; 1999 Feb; 26(2):504-7. PubMed ID: 9972996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OMERACT 2023 Systemic Lupus Erythematosus Special Interest Group: Winnowing and Binning Preliminary Candidate Domains for the Core Outcome Set.
    Nielsen W; Strand V; Simon LS; Parodis I; Kim AHJ; Desai M; Enman Y; Wallace D; Chaichian Y; Navarra S; Aranow C; MacKay M; Trotter K; Tayer-Shifman OE; Duarte-Garcia A; Shan Tam L; Ugarte-Gil MF; PonsEstel GJ; Reynolds JA; Nikpour M; Hoi A; Romero-Diaz J; Papachristos D; Aggarwal A; Mok CC; Fujio K; Ramsey-Goldman R; Howe A; Kia BN; Bonilla D; Thumboo J; Mosca M; Aringer M; Johnson SR; Drucker AM; Morand E; Bruce I; Touma Z;
    Semin Arthritis Rheum; 2024 Apr; 65():152380. PubMed ID: 38281467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.
    Ruperto N; Ravelli A; Cuttica R; Espada G; Ozen S; Porras O; Sztajnbok F; Falcini F; Kasapcopur O; Venning H; Bica B; Merino R; Coto C; Ros J; Susic G; Gamir ML; Minden K; See Y; Uziel Y; Mukamel M; Riley P; Zulian F; Olivieri AN; Cimaz R; Girschick H; Rumba I; Cavuto S; Pistorio A; Lovell DJ; Martini A; ;
    Arthritis Rheum; 2005 Sep; 52(9):2854-64. PubMed ID: 16142708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.
    Ruperto N; Ravelli A; Oliveira S; Alessio M; Mihaylova D; Pasic S; Cortis E; Apaz M; Burgos-Vargas R; Kanakoudi-Tsakalidou F; Norambuena X; Corona F; Gerloni V; Hagelberg S; Aggarwal A; Dolezalova P; Saad CM; Bae SC; Vesely R; Avcin T; Foster H; Duarte C; Herlin T; Horneff G; Lepore L; van Rossum M; Trail L; Pistorio A; Andersson-Gäre B; Giannini EH; Martini A;
    Arthritis Rheum; 2006 Jun; 55(3):355-63. PubMed ID: 16739203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology.
    Wolfe F; Lassere M; van der Heijde D; Stucki G; Suarez-Almazor M; Pincus T; Eberhardt K; Kvien TK; Symmons D; Silman A; van Riel P; Tugwell P; Boers M
    J Rheumatol; 1999 Feb; 26(2):484-9. PubMed ID: 9972992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.
    Boers M; Idzerda L; Kirwan JR; Beaton D; Escorpizo R; Boonen A; Magasi S; Sinha I; Stucki G; Tugwell P
    J Rheumatol; 2014 May; 41(5):978-85. PubMed ID: 24584922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICF core sets: how to specify impairment and function in systemic lupus erythematosus.
    Aringer M; Stamm TA; Pisetsky DS; Yarboro CH; Cieza A; Smolen JS; Stucki G
    Lupus; 2006; 15(4):248-53. PubMed ID: 16686267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
    Tillett W; Eder L; Goel N; De Wit M; Gladman DD; FitzGerald O; Campbell W; Helliwell PS; Gossec L; Orbai AM; Ogdie A; Strand V; McHugh NJ; Mease PJ
    J Rheumatol; 2015 Nov; 42(11):2198-203. PubMed ID: 25934828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.
    Hatemi G; Ozguler Y; Direskeneli H; Mahr A; Gul A; Levi V; Aydin SZ; Mumcu G; Sertel-Berk O; Stevens RM; Yazici H; Merkel PA
    J Rheumatol; 2015 Dec; 42(12):2436-41. PubMed ID: 26373563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions.
    Strand V
    Lupus; 2004; 13(5):406-11. PubMed ID: 15230300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updating the OMERACT filter at OMERACT 11.
    Kirwan JR; Boers M; Tugwell P
    J Rheumatol; 2014 May; 41(5):975-7. PubMed ID: 24788466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research.
    Mikdashi J; Nived O
    Arthritis Res Ther; 2015 Jul; 17(1):183. PubMed ID: 26189728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials.
    Bertsias G; Gordon C; Boumpas DT
    Lupus; 2008 May; 17(5):437-42. PubMed ID: 18490423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.